 Home > Active Ingredient News > Immunology News > The world's first innovative dual-target biological agent for the treatment of systemic lupus erythematosus (SLE), Tatacept is the first to be launched in China!

The world's first innovative dual-target biological agent for the treatment of systemic lupus erythematosus (SLE), Tatacept is the first to be launched in China!

 Last Update: 2021-04-17
 Source: Internet
 Author: User

Tags

magic drug

drug delivery devices

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Yu "wolf" has the skill, China embarks on a new journey of SLE dual target

The world's first innovative dual-target biological agent for SLE treatment, Tatacept is the first to be marketed in China

20 2 1 Nian 4 Yue 1 1 Ri , the theme of "new love Ty heart" Global 's first dual-target treatment of systemic lupus erythematosus Wolf sores (SLE ) is innovation a class of biological drugs Thai Love ^®(generic name: Thai West it S & P) and Guo listed grandly in Beijing held office.

20 2 1 Nian 4 Yue 1 1 Ri , the theme of "new love Ty heart" Global 's first dual-target treatment of systemic lupus erythematosus Wolf sores (SLE ) is innovation a class of biological drugs Thai Love ^® ®(generic name: Thai it Sipp) and Guo listed grandly in Beijing held office.

Launching ceremony of the listing meeting

The participation of many majors in the field of rheumatism has laid the top academic foundation for the treatment of systemic lupus erythematosus.

Experts gathered at this new product launch, and some important guests were present (in no particular order).

Professor Zhao Yan , Professor Zeng Xiaofeng, Professor Zhang Fengchun, Professor Li Zhan-Guo, Professor Zhang Zhuoli, Professor Huang Chi wave, Professor Yang Chengde, Professor Zhang Xuan, professor Limeng Tao, Professor Bao Chunde, Professor Huang Feng, professor of ancient clean if Professor Xu Hu Ji, a professor Zhu Ping, Professor Zhang Zhiyi, Professor Liu Yi , Wang Li strong, Zhang Miao Jia, Professor Dai Lie, Professor Yang Niansheng, Professor Ho Lan, Lin Jin, Professor Ye cream, Professor Zhang, Professor Wu Lijun national experts in the field of rheumatoid pro- pro conference site , A total of "planning" the world's first SLE dual-target therapy new era .

In the country's contribution to the contributor

Targeted BLyS /APRIL inhibitor therapy has become an indispensable treatment option for SLE

Targeting Targeting of BLyS of BLyS / of APRIL / of APRIL inhibitor therapy has become the treatment of choice SLE indispensable inhibitor therapy has become an indispensable treatment options SLE

Lupus erythematosus is a typical self- immune connective tissue disease, SLE lupus erythematosus is the most common, but also various types of lupus erythematosus is the most serious type, mainly in the 15 to 45-year-old women of childbearing age.

Professor Li Mengtao from Peking Union Medical College Hospital talks about the new progress of targeted B cell therapy for SLE

Professor Li Mengtao from Peking Union Medical College Hospital talks about the new progress of targeted B cell therapy for SLE Peking Union Medical College Hospital

The pathogenesis of SLE is complex, there are huge challenges in treatment, and drug development is difficult.

With the development of medicine, biological targeted drugs are constantly trying new explorations .

Professor Zhang Fengchun from Peking Union Medical College introduces the Phase Ⅱb clinical study of Taltazep in the treatment of SLE

It is reported that, as an innovative drug with “outstanding efficacy”, Taltazep has obtained the national priority review qualification and has been approved for SLE indications.

Qualitative leap

Creating new dual target drugs effectively reduce recurrence in patients with SLE security escort

Chong hit new two- new dual target target pharmaceutical drugs effectively reduce recurrence in patients with SLE security escort effectively reduce the recurrence for patients with SLE security escort

The past 20 years, SLE treatment from the treatment of helpless, but now Thai listed investment Sipp it into clinical bed, all- new dual target mechanism will effectively improve the prognosis of patients, raise high the patient quality of life .

Professor Zhang Zhuoli from Peking University First Hospital introduces the safety of Taltazep

Significant research data shown for more than a lower deterioration of its Thai BILAG index placebo treatment group Heap PGA score scale and the proportion of deteriorated.

Significant research data shown for more than a lower deterioration of its Thai BILAG index placebo treatment group Heap PGA score scale and the proportion of deteriorated.
Basic and clinical research data show that in terms of improvement in immunological indicators, Tetazep can significantly reduce the patient's serum immunoglobulin levels (IgG, IgA, IgM) , but it can always be maintained above the normal value.
Complement (C3) , C4) increased significantly , with the time was not observed unexpected adverse reactions, exhibits better security tolerated.
The elimination half-life of the fusion protein is shorter than that of the monoclonal antibody ( t _1/2 1/2 11.
8 days vs 19.
4 days), and at the same time , Taltazep down-regulates the level of immunoglobulin in a dose-dependent manner.
If there is a clinical safety problem, it can be based on the actual situation.
The dosage can be changed or stopped at any time, and the use is more flexible.
Strong and powerful Zhong Guo good voice again stunning whole field .

Professor Yan Zhao from Peking Union Medical College Hospital introduced the mechanism of targeting BLyS/APRIL in the treatment of SLE

Dual-target therapy is a milestone progress in the development of SLE diagnosis and treatment .
As the world's first dual-targeted biological new drug targeting BLyS and APRIL, the first launch of Taltazep in China will open a new dual-target therapy for SLE in China.
The gate of the times, the powerful mechanism of dual targets and the innovative fusion protein structure will provide Chinese rheumatologists with a new therapeutic tool for SLE.
Taltazep has proved to the world that in the field of major diseases, Chinese original drugs are capable of better solving the clinical needs of Chinese patients, and have excellent efficacy and safety ; this also reflects the contribution of Chinese innovative drugs in the field of rheumatism , And hopefully lead the treatment practice in the field of SLE in China and even the world.

Not to be on

Not not to be on to be stage

Zhong country create a new Medicare drug substance into the country the international hall to benefit the world suffering person

In the country's national record record new original drug new Medicare drug substance into the country was entering the country the occasion of the international halls of benefit palace benefit the world's global risk patients who were

，，SLE，，。，FDA，III，，SLE。

，，SLE，，。，FDA，FDAIII，，SLE。

，，，IgA、、、Ⅱ/Ⅲ，，。

：

[1] Lee YH,et al.
Lupus.
2016 Jun;25(7):727-34.

[2] 2020[J].
,2020(03):172-185

[3] Yang B,et al.
Front Immunol.
2020;11 539797.

[4] .
Samotij D,Reich A.
Biomed Res Int.
2019;2019: 8142368.

[5] .
RC18.

[6] Wu et al,2000,The Journal of Biological Chemistry, 275: 35478-35485

[7] Hymowitz SG,et al.
J Biol Chem,2005,280(8) :72187227.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.